Clinical trials: Pulmonary Hypertension
Pulmonary Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH).
- Trial name
- CHORUS (NCT07839585)
- Testing
- Sotatercept
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
This Phase 2 study was to determine the incidence of increased serum aminotransferase concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as well as the overall safety and tolerability of…
- Trial name
- NCT00423592
- Testing
- ambrisentan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
the purpose of this study is: To assess the effect of BIA 5 1058 400 mg on the PK of bosentan. To assess the effect of bosentan on the PK of BIA 5 1058
- Trial name
- NCT04991207
- Testing
- BIA 5-1058, bosentan
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to improve exercise capacity and delay clinical worsening.
- Trial name
- LIBERTY2 (NCT02736149)
- Testing
- ubenimex
- Where
- 28 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Eiger BioPharmaceuticals
Pulmonary Arterial Hypertension
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).
- Trial name
- NCT02304198
- Testing
- Udenafil
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Dong-A ST Co., Ltd.
Pulmonary Hypertension, Interstitial Lung Disease
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT07816185
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 3 sites in United States
- Volunteers
- 376 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Arterial Hypertension
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
- Trial name
- NCT00159874
- Testing
- Sildenafil citrate
- Where
- 39 sites in United States, Brazil and 13 more
- Volunteers
- 234 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
IMPAHCT-FUL: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (LTE) Trial was a follow up study to establish the long-term safety of AV-101.
- Trial name
- IMPAHCT-FUL (NCT05557942)
- Testing
- AV-101
- Where
- 72 sites in United States, Argentina and 18 more
- Volunteers
- 186 people
- Sponsor
- Aerovate Therapeutics
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Pulmonary Arterial Hypertension
DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study
The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when used with the Medtronic SynchroMed® II Implantable Infusion System to deliver…
- Trial name
- DelIVery (NCT01321073)
- Testing
- Model 10642 Implantable Intravascular Catheter
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH.
- Trial name
- LIGHTRAY EXT (NCT06925750)
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 73 sites in United States, Argentina and 17 more
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC